Age group | Total | |||||
---|---|---|---|---|---|---|
<5 | 5–12 | 13–59 | ≥60 | NK | ||
n = 610 (21.6%) | n = 317 (11.2%) | n = 1,716 (60.6%) | n = 157 (5.5%) | n = 31 (1.1%) | N = 2,831 | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Gender | ||||||
Male | 315 (51.6) | 151 (47.6) | 606 (35.3) | 48 (30.6) | 16 (51.6) | 1,136 (40.1) |
Female | 295 (48.4) | 166 (52.4) | 1,110 (64.7) | 109 (69.4) | 15 (48.4) | 1,695 (59.9) |
Facility type | ||||||
Community pharmacy | 4 (0.7) | 1 (0.3) | 18 (1.1) | 3 (1.9) | 0 (0) | 26 (0.9) |
Government | 599 (98.2) | 312 (98.4) | 1,621 (94.5) | 153 (97.5) | 31 (100) | 2,716 (95.9) |
Private clinic | 4 (0.7) | 1 (0.3) | 27 (1.6) | 0 (0) | 0 (0) | 32 (1.1) |
Quasi-government | 3 (0.5) | 3 (1.0) | 50 (2.9) | 1 (0.6) | 0 (0) | 57 (2.0) |
Mode of diagnosis | ||||||
Doctor | 501 (82.1) | 242 (76.4) | 1,383 (80.6) | 125 (79.6) | 18 (58.1) | 2,269 (80.2) |
Laboratory Confirmation | 20 (3.3) | 19 (6.0) | 48 (2.8) | 3 (1.9) | 1 (3.2) | 91 (3.2) |
Other health professional | 18 (3.0) | 22 (6.9) | 127 (7.4) | 8 (5.1) | 5 (16.1) | 180 (6.4) |
Pharmacist | 0 (0) | 0 (0) | 10 (0.6) | 1 (0.6) | 0 (0) | 11 (0.4) |
Self | 0 (0) | 2 (0.6) | 6 (0.4) | 0 (0) | 0(0) | 8 (0.3) |
Unknown | 71 (11.6) | 32 (10.1) | 142 (8.3) | 20 (12.7) | 7 (22.6) | 272 (9.6) |
Anti-malarial treatment prescribed | ||||||
Combination therapy (ART-AQ) | 161 (26.4) | 181 (57.1) | 790 (46.0) | 76 (48.4) | 9 (29.0) | 1,217 (43.0) |
Combination therapy (Other ACT) | 240 (39.3) | 40 (12.6) | 124 (7.2) | 5 (3.2) | 9 (29.0) | 418 (14.8) |
Monotherapy (Artemisinin based) | 111 (18.2) | 55 (17.4) | 700 (40.8) | 61 (38.9) | 9 (29.0) | 936 (33.1) |
Monotherapy (Non-artemisinin) | 98 (16.1) | 41 (12.9) | 102 (5.9) | 15 (9.6) | 4 (12.9) | 260 (9.2) |